A typical pattern observed in M/EEG recordings of Mild Cognitive Impairment (MCI) patients progressing to Alzheimer's disease is a continuous slowing of brain oscillatory activity. Definitions of oscillatory slowing are imprecise, as they average across time and frequency bands, masking the finer structure in the signal and potential reliable biomarkers of the disease. Recent studies show that high averaged band power can result from transient increases in power, termed 'events' or 'bursts'. To better understand MEG oscillatory slowing in AD progression, we analyzed features of high-power oscillatory events and their relationship to cognitive decline. MEG resting-state oscillations were registered in age-matched patients with MCI who later convert (CONV, N=41) or do not convert (NOCONV, N=44) to AD, in a period of 2.5 years. To distinguish future CONV from NOCONV, we characterised the rate, duration, frequency span and power of transient high-power events in the alpha and beta band in anterior cingulate (ACC) and precuneus (PC). Results revealed event-like patterns in resting-state power in both the alpha and beta-bands, however only beta-band features were predictive of conversion to AD, particularly in PC. Specifically, compared to NOCONV, CONV had a lower number of beta events, along with lower power events and a trend toward shorter duration events in PC (p < 0.05). Beta event durations were also significantly shorter in ACC (p < 0.01). Further, this reduced expression of beta events in CONV predicted lower values of mean relative beta power, increased probability of AD conversion, and poorer cognitive performance. Our work paves the way for reinterpreting M/EEG slowing and examining beta event features as a new biomarker along the AD continuum, and a potential link to theories of inhibitory cognitive control in neurodegeneration. These results may bring us closer to understanding the neural mechanisms of the disease that help guide new therapies.

The authors have declared no competing interest.

This work was supported by funds from NIH and the Collaborative Research in Computational Neuroscience (CRCNS) under the project 'Interpreting MEG Biomarkers of Alzheimer's Progression with Human Neocortical Neurosolver'. UCM-Santander grants for PhD students, provided additional economical support to main author.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of Hospital Clinico Universitario San Carlos in Madrid, Spain gave ethical approval for this work. All participants provided written informed consent prior to participation.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors